Skip to main content
SpringerLink
Log in

Guide to Drug Therapy for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Obstruction

Implications for Sexual Dysfunction

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The relationship between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) caused by benign prostatic obstruction (BPO) has recently gained increasing attention. Both BPO and ED are highly prevalent in older men and both conditions frequently contribute to a reduction in overall quality of life.

Current medical treatment of LUTS/BPO consists of monotherapy with α1-adrenoceptor antagonists or 5α-reductase inhibitors, a combination of these two agents or, in some cases, various phytotherapeutic approaches. When choosing a drug therapy, it is important to recognize that while 5α-reductase inhibitors increase the risk of ED and ejaculatory disorders, and combined therapy carries the cumulative risk of causing sexual dysfunction, some α1-adrenergic receptor antagonists have been reported to improve overall sexual function. Therefore, the successful evaluation and management of older men with LUTS associated with BPO should include an assessment of baseline sexual function and subsequent monitoring of medication-induced sexual adverse effects.

In this review, we detail the pathophysiological mechanisms involved in LUTS/BPO-associated ED, including reduced nitric oxide/cyclic guanosine monophosphate system activity, enhanced endothelin-1/rhoA/rho kinase pathway activity, sympathetic overactivity, pelvic organ atherosclerosis and potential preventive approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824–37

    PubMed  Google Scholar 

  2. Rosen R, Catania J, Pollack L, et al. Male Sexual Health Questionaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777–82

    PubMed  Google Scholar 

  3. Lukacs B. Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 14–20

    PubMed  Google Scholar 

  4. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999: 281; 537–44

    PubMed  CAS  Google Scholar 

  5. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–11

    PubMed  CAS  Google Scholar 

  6. Braun MH, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘Aging Male’ symptoms? Results of the ‘Cologne Male Survey’. Eur Urol 2003; 44: 588–4

    PubMed  CAS  Google Scholar 

  7. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–5

    PubMed  CAS  Google Scholar 

  8. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: analysis of risk factors. J Sex Med 2006; 3: 144–9

    PubMed  Google Scholar 

  9. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–49

    PubMed  Google Scholar 

  10. McVary KT, Foley J, Bautista O, et al. The association of lower urinary tract symptoms (LUTS) with sexual function in men participating in a clinical trial of medical therapy for benign prostatic hyperplasia [abstract]. J Urol 2003; 169 Suppl. 322: A1252

    Google Scholar 

  11. Vallancien G, Emberton M, Harving N, et al. Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–61

    Google Scholar 

  12. Bruschini H, Schmidt RA, Tanagho EA. The male genitourinary sphincter mechanism in the dog. Invest Urol 1978; 15: 284–7

    PubMed  CAS  Google Scholar 

  13. Smith ER, Lebeaux MI. The mediation of the canine prostatic secretion provoked by hypogastric nerve stimulation. Invest Urol 1970; 7: 313–8

    PubMed  CAS  Google Scholar 

  14. Burnett AL. Nitric oxide control of lower genitourinary tract functions: a review. Urology 1995; 45: 1071–83

    PubMed  CAS  Google Scholar 

  15. Abrams P. Benign prostatic hyperplasia has precise meaning [letter]. BMJ 2001; 322: 106

    PubMed  CAS  Google Scholar 

  16. Goldenberg SL. Prostatism: nature of the symptoms. Can J Urol 1997; 4 Suppl. 1: 3–5

    PubMed  Google Scholar 

  17. Bostwick DG. Prostatic intraepithelial neoplasia (PIN): current concepts. J Cell Biochem 1992; 16H: 10–9

    CAS  Google Scholar 

  18. Silverman WM. J Am Osteopath Assoc 2004; 104 (2 Suppl. 2): S1–4

    PubMed  Google Scholar 

  19. Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms [editorial]. Rev Urol 1999; 1: 65

    PubMed  CAS  Google Scholar 

  20. Burnstock G. Cholinergic, adrenergic, and purinergic neuromuscular transmission. Fed Proc 1977; 36: 2434–8

    PubMed  CAS  Google Scholar 

  21. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428–6

    PubMed  CAS  Google Scholar 

  22. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267–73

    PubMed  Google Scholar 

  23. Chaikin DC, Blaivas JG. Voiding dysfunction: definitions. Curr Opin Urol 2000; 11: 395–8

    Google Scholar 

  24. Novara G, Galfano A, Ficarra V, et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006; 50: 675–83

    PubMed  CAS  Google Scholar 

  25. deGroat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006; 147 Suppl. 2: S25–40

    PubMed  Google Scholar 

  26. Schafer W, Abrams P, Liao L, et al. International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002; 21: 261–74

    Google Scholar 

  27. Mazzucco R. American Urological Association: 96th Annual Meeting; 2001 Jun 2–7; Anaheim (CA). IDrugs 2001; 4: 892–5

    Google Scholar 

  28. Porru D, Bartoletti R, Austoni E, et al. Relationship of flow rate with symptoms, quality of life and other clinical parameters in patients with LUTS suggestive of BPH. Eur Urol 2001; 40 Suppl. 1: 23–7

    PubMed  Google Scholar 

  29. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–14; discussion 1314-15

    PubMed  Google Scholar 

  30. Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin North Am 2007; 36: 453–63

    PubMed  Google Scholar 

  31. Polloack JS, Fostermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium derived relaxing factor syntase from cultured and native bovive aortic cells. Proc Natl Acad Sci U S A 1991; 88: 10480–4

    Google Scholar 

  32. Bivalacqua TJ, Musicki B, Usta MS, et al. Endothelial nitric oxide syntase gene therapy for erectile dysfunction. Curr Pharm Design 2005; 11: 4059–67

    CAS  Google Scholar 

  33. El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005; 96: 1079–86

    PubMed  CAS  Google Scholar 

  34. Clement P, Bernabe J, Kia HK, et al. D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N-propylamino) tetralin in rats. J Pharmacol Exp Ther 2006; 316: 830–4

    PubMed  CAS  Google Scholar 

  35. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802–13

    PubMed  CAS  Google Scholar 

  36. Rosen RC, Seidman SN, Menza MA, et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004; 16: 334–40

    PubMed  CAS  Google Scholar 

  37. Andersson KE, Gratzke C. Pharmacology of alphal-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007; 4: 368–78

    PubMed  CAS  Google Scholar 

  38. Russell S, McVary KT. Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. Curr Urol Rep 2005; 6: 445–53

    PubMed  Google Scholar 

  39. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998; 160: 1358–67

    CAS  Google Scholar 

  40. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193–202

    PubMed  CAS  Google Scholar 

  41. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002; 19: 390–6

    PubMed  CAS  Google Scholar 

  42. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003; 169: 1520–5

    PubMed  CAS  Google Scholar 

  43. Paick JS, Ku JH, Shin JW, et al. Alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. BJU Int 2006; 97: 1017–23

    PubMed  CAS  Google Scholar 

  44. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174 (4 Pt 1): 1334–8

    PubMed  CAS  Google Scholar 

  45. Chappie CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50–6

    Google Scholar 

  46. De Rose AF, Carmignani G, Corbu C, et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002; 68: 95–8

    PubMed  Google Scholar 

  47. Kirby RS, Andersen M, Gratzke P, et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192–200

    PubMed  CAS  Google Scholar 

  48. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678–87

    PubMed  CAS  Google Scholar 

  49. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8 Suppl. 4: S3–9

    PubMed  Google Scholar 

  50. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007; 29: 17–25

    PubMed  CAS  Google Scholar 

  51. Nishino Y, Masue T, Miwa K, et al. Comparison of two alphal-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006; 97: 747–51; discussion 751

    PubMed  CAS  Google Scholar 

  52. McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol 2006; 175: 35–42

    PubMed  CAS  Google Scholar 

  53. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717–23

    PubMed  CAS  Google Scholar 

  54. Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10mg once daily: a 2-year experience in ‘real-life’ practice. BJU Int 2006; 97: 513–9

    PubMed  CAS  Google Scholar 

  55. Blue DR, Daniels DV, Gever JR, et al. Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int 2004; 93: 162–70

    PubMed  CAS  Google Scholar 

  56. Sugaya K, Nishijima S, Miyazato M, et al. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002; 328: 74–6

    PubMed  CAS  Google Scholar 

  57. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170 (2 Pt 1): 530–47

    Google Scholar 

  58. Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996; 119: 797–803

    PubMed  CAS  Google Scholar 

  59. Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis 2001; 4 Suppl. 1: S12–6

    PubMed  Google Scholar 

  60. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006; 28: 13–25

    PubMed  Google Scholar 

  61. van Moorselaar RJ, Hartung R, Emberton M, et al. ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603–8

    Google Scholar 

  62. Kaminetsky J. Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 2006; 22: 2497–506

    PubMed  Google Scholar 

  63. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997; 157: 525–30

    CAS  Google Scholar 

  64. Bartsch G, Fitzpatrick JM, Schalken JA, et al. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004; 93 Suppl. 1: 27–9

    PubMed  Google Scholar 

  65. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338–62

    PubMed  CAS  Google Scholar 

  66. Roehrborn CG, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 642–50

    PubMed  CAS  Google Scholar 

  67. AUA Guidelines on Management of Benign Prostatic Hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530–47

    Google Scholar 

  68. Johnson 2nd TM, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170: 145–8

    PubMed  Google Scholar 

  69. Roehrborn CG. The clinical benefits of dutasteride treatment for LUTS and BPH. Rev Urol 2004; 6 Suppl. 9: S22–30

    PubMed  Google Scholar 

  70. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001; 58: 17–24

    PubMed  CAS  Google Scholar 

  71. Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999; 53: 690–5

    CAS  Google Scholar 

  72. O'Leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92: 262–6

    PubMed  Google Scholar 

  73. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461–6

    PubMed  CAS  Google Scholar 

  74. McConnell JD, Roehrborn CG, Bautista OM, et al. The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–98

    PubMed  CAS  Google Scholar 

  75. Bales GT, Christiano AP, Kirsh EJ, et al. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 1999; 54: 86–9

    PubMed  CAS  Google Scholar 

  76. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604–9

    PubMed  CAS  Google Scholar 

  77. Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002; 29: 23–9

    PubMed  Google Scholar 

  78. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2002; 3: 285–91

    PubMed  Google Scholar 

  79. Zlotta AR, Teillac P, Raynaud JP, et al. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 2005; 48: 269–76

    PubMed  CAS  Google Scholar 

  80. Debruyne F, Koch G, Boyle P, et al. Groupe d'etude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [in French]. Prog Urol 2002; 12: 384–92; discussion 394

    Google Scholar 

  81. Vela-Navarrete R, Escribano-Burgos M, Farre AL, et al. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 2005; 173: 507–10

    PubMed  Google Scholar 

  82. Wadsworth TL, Carroll JM, Mallinson RA, et al. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004; 145: 3205–14

    PubMed  CAS  Google Scholar 

  83. Arruzazabala ML, Mas R, Carbajal D, et al. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on in vitro and in vivo effects mediated by alpha-adrenoceptors in rats. Drugs 2005; 6: 281–9

    CAS  Google Scholar 

  84. Agartan CA, Whitbeck C, Sokol R, et al. Protection of urinary bladder function by grape suspension. Phytother 2004; 18: 1013–8

    Google Scholar 

  85. Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997; 33: 1–8

    PubMed  CAS  Google Scholar 

  86. Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000; 109: 654–64

    PubMed  CAS  Google Scholar 

  87. Levin RM, Whitbeck C, Horan P, et al. Low-dose tadenan protects the rabbit bladder from bilateral ischemia/reperfusioninduced contractile dysfunction. Phytomedicine 2005; 12(1–2): 17–24

    PubMed  CAS  Google Scholar 

  88. Yoshimura Y, Yamaguchi O, Bellamy F, et al. Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. Urology 2003; 61: 474–8

    PubMed  Google Scholar 

  89. Lepor H. Landmark studies impacting the medical management of benign prostatic hyperplasia. Rev Urol 2003; 5 Suppl. 5: S28–35

    PubMed  Google Scholar 

  90. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–45

    PubMed  Google Scholar 

  91. Hedlund P. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract-is there a basis for pharmacological targeting of cGMP? World J Urol 2005; 23: 362–7

    PubMed  CAS  Google Scholar 

  92. Deng CH, Chen HR, Qiu SP, et al. Effect of nitric oxide donor and alphal-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro. Zhonghua Wai Ke Za Zhi 2004; 42: 201–4

    PubMed  Google Scholar 

  93. Klotz T, Mathers MJ, Bloch W, et al. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999; 31: 335–41

    PubMed  CAS  Google Scholar 

  94. Deka DK, Brading AF. Nitric oxide activates glibenclamidesensitive K+ channels in urinary bladder myocytes through a c-GMP-dependent mechanism. Eur J Pharmacol 2004; 492: 13–9

    PubMed  CAS  Google Scholar 

  95. Kedia G, Uckert S, Scheller F, et al. In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 2006; 67: 1292–7

    PubMed  Google Scholar 

  96. Gradini R, Realacci M, Ginepri A, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999; 189: 224–9

    PubMed  CAS  Google Scholar 

  97. Stothers L, Laher I, Christ GT. A review of the L-arginine: nitric oxide: guanylate cyclase pathway as a mediator of lower urinary tract physiology and symptoms. Can J Urol 2003; 10: 1971–80

    PubMed  Google Scholar 

  98. Cellek S. Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction. Drugs Today (Barc) 2000; 36: 135–46

    CAS  Google Scholar 

  99. Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002; 94: 93–112

    PubMed  CAS  Google Scholar 

  100. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005; 40(3): 121–8

    PubMed  Google Scholar 

  101. Kim NN, Dhir V, Azadzoi KM, et al. Pilot study of the endothelin-A receptor selective antagonist BMS-193884 for the treatment of erectile dysfunction. J Androl 2002; 23: 76–83

    PubMed  CAS  Google Scholar 

  102. Wingard CJ, Lewis R, Mills TM. Erection and NO override the vasoconstrictive effect of alpha-adrenergic stimulation in the rat penile vasculature. Int J Impot Res 2001; 13: 212–20

    PubMed  CAS  Google Scholar 

  103. Filippi S, Marini M, Vannelli GB, et al. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Mol Hum Reprod 2003; 9: 765–74

    PubMed  CAS  Google Scholar 

  104. Wingard CJ, Husain S, Williams J, et al. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1145–52

    PubMed  CAS  Google Scholar 

  105. Andersson KE. Detrusor contraction. Scand J Urol Nephrol Suppl 2004; 215: S54–7

    Google Scholar 

  106. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rhokinase inhibitor (S)-(+)-2-methyl-l-[(4-methyl-5-isoquinolinyl) sulfonyl]homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther 2005; 315: 155–62

    PubMed  CAS  Google Scholar 

  107. Chang S, Hypolite JA, Zderic SA, et al. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1124–30

    PubMed  CAS  Google Scholar 

  108. Kajioka S, Nakayama S, McCoy R, et al. Inward current oscillation underlying tonic contraction caused via ETA receptors in pig detrusor smooth muscle. Am J Physiol Renal Physiol 2004; 286: F77–85

    PubMed  CAS  Google Scholar 

  109. Wada Y, Latifpour J, Sanematsu H, et al. Age-related changes in contractile responses of rabbit lower urinary tract to endothelin. J Urol 2000; 164: 806–13

    PubMed  CAS  Google Scholar 

  110. Imajo C, Waiden PD, Shapiro E, et al. Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate. J Urol 1997; 158: 253–7

    PubMed  CAS  Google Scholar 

  111. Wu-Wong JR, Chiou WJ, Saeed B, et al. Endothelin receptor in benign prostatic hyperplastic cells: binding and functional studies. Recept Signal Transduct 1997; 7: 165–75

    PubMed  CAS  Google Scholar 

  112. Donoso MV, Salas C, Sepulveda G, et al. Involvement of ETA receptors in the facilitation by endothelin-1 of non-adrenergic non-cholinergic transmission in the rat urinary bladder. Br J Pharmacol 1994; 111: 473–82

    PubMed  CAS  Google Scholar 

  113. Raschack M, Gock S, Unger L, et al. LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions. J Cardiovasc Pharmacol 1998; 31: S241–4

    PubMed  CAS  Google Scholar 

  114. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase Ha study. J Neurosurg 2005; 103: 9–17

    PubMed  CAS  Google Scholar 

  115. Michaelson MD, Kaufman DS, Kantoff P, et al. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006; 107: 530–5

    PubMed  CAS  Google Scholar 

  116. Rees RW, Foxwell NA, Ralph DJ, et al. Y-27632, a Rhokinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170 (6 Pt 1): 2517–22

    PubMed  CAS  Google Scholar 

  117. Takahashi R, Nishimura J, Hirano K, et al. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004; 172: 748–52

    PubMed  CAS  Google Scholar 

  118. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rhokinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004; 101: 9121–6

    PubMed  CAS  Google Scholar 

  119. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007; 26 Suppl. 6: 948–54

    PubMed  CAS  Google Scholar 

  120. Calvert RC, Mumtaz FH, Dashwood MR, et al. Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. Clin Sci (Lond) 2002; 103 Suppl. 48: 459–63S

    Google Scholar 

  121. Hall IP. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Clin Pharmacol 1993; 35: 1–7

    PubMed  CAS  Google Scholar 

  122. Tinel H, Stelte-Ludwig B, Hutter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating be-nign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259–63

    PubMed  CAS  Google Scholar 

  123. Uckert S, Kuthe A, Jonas U, et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484–90

    PubMed  CAS  Google Scholar 

  124. Qiu Y, Kraft P, Craig EC, et al. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002; 59: 145–9

    PubMed  Google Scholar 

  125. Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64: 533–46

    PubMed  CAS  Google Scholar 

  126. Dokita S, Smith SD, Nishimoto T, et al. Involvement of nitric oxide and cyclic GMP in rabbit urethral relaxation. Eur J Pharmacol 1994; 266: 269–75

    PubMed  CAS  Google Scholar 

  127. Uckert S, Oelke M, Stief CG, et al. Immunohistochemical Distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49: 740–5

    PubMed  Google Scholar 

  128. Giuliano F, Kaplan SA, Cabanis MJ, et al. Hemodynamic interaction study between the alphal-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67: 1199–204

    PubMed  Google Scholar 

  129. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276–81

    PubMed  CAS  Google Scholar 

  130. Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007; 69: 25–6

    PubMed  CAS  Google Scholar 

  131. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836–9

    PubMed  CAS  Google Scholar 

  132. Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662–7

    PubMed  CAS  Google Scholar 

  133. McVary KT, Monnig W, Camps Jr JL, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–7

    PubMed  CAS  Google Scholar 

  134. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Section of Andrology, Department of Urology, Tulane University, Health Sciences Center, 1430 Tulane Avenue, New Orleans, SL-42, Louisiana, 70112, USA

    Serap Gur, Philip J. Kadowitz & Wayne J. G. Hellstrom M.D., F.A.C.S.

Authors
  1. Serap Gur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip J. Kadowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wayne J. G. Hellstrom M.D., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wayne J. G. Hellstrom M.D., F.A.C.S..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gur, S., Kadowitz, P.J. & Hellstrom, W.J.G. Guide to Drug Therapy for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Obstruction. Drugs 68, 209–229 (2008). https://doi.org/10.2165/00003495-200868020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868020-00005

Keywords

Search

Navigation